Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H12BrNO |
Molecular Weight | 254.123 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCNC(=O)\C=C\C1=CC(Br)=CC=C1
InChI
InChIKey=LDCXGZCEMNMWIL-VOTSOKGWSA-N
InChI=1S/C11H12BrNO/c1-2-13-11(14)7-6-9-4-3-5-10(12)8-9/h3-8H,2H2,1H3,(H,13,14)/b7-6+
Cinromide possesses antiepileptic activity in various animal models. However, in the experiments for human, this drug had a very limited clinical usefulness and was withdrawn from testing by its manufacturer. The lack of an antiepileptic response may have been due to factors other than species differences but indicates that a positive result of a drug in animal models is not the sole factor necessary to predict beneficial antiepileptic activity in humans. In addition, cinromide was studied for the patients with Lennox-Gastaut Syndrome, as a result, there was no difference between cinromide and placebo in terms of seizure reduction or global evaluations.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Cinromide (3-bromo-N-ethylcinnanamide), novel anticonvulsant agent. | 1981 Nov |
|
Effect of cinromide on inhibitory and excitatory mechanisms. | 1983 Aug |
|
Cinromide in the treatment of absence seizures. | 1983 Aug |
|
Influence of cinromide on metrazol--induced seizures during ontogenesis in rats. | 1988 |
|
Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut Syndrome. The Group for the Evaluation of Cinromide in the Lennox-Gastaut Syndrome. | 1989 Jul-Aug |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6409599
Doses of cinromide ranged from 1,200 to 4,800 mg/day, depending on patient response.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m1074
Created by
admin on Fri Dec 15 17:27:17 UTC 2023 , Edited by admin on Fri Dec 15 17:27:17 UTC 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL93233
Created by
admin on Fri Dec 15 17:27:17 UTC 2023 , Edited by admin on Fri Dec 15 17:27:17 UTC 2023
|
PRIMARY | |||
|
DTXSID7046417
Created by
admin on Fri Dec 15 17:27:17 UTC 2023 , Edited by admin on Fri Dec 15 17:27:17 UTC 2023
|
PRIMARY | |||
|
4227
Created by
admin on Fri Dec 15 17:27:17 UTC 2023 , Edited by admin on Fri Dec 15 17:27:17 UTC 2023
|
PRIMARY | |||
|
688145
Created by
admin on Fri Dec 15 17:27:17 UTC 2023 , Edited by admin on Fri Dec 15 17:27:17 UTC 2023
|
PRIMARY | |||
|
M197KE7A5N
Created by
admin on Fri Dec 15 17:27:17 UTC 2023 , Edited by admin on Fri Dec 15 17:27:17 UTC 2023
|
PRIMARY | |||
|
3102
Created by
admin on Fri Dec 15 17:27:17 UTC 2023 , Edited by admin on Fri Dec 15 17:27:17 UTC 2023
|
PRIMARY | |||
|
100000081094
Created by
admin on Fri Dec 15 17:27:17 UTC 2023 , Edited by admin on Fri Dec 15 17:27:17 UTC 2023
|
PRIMARY | |||
|
58473-74-8
Created by
admin on Fri Dec 15 17:27:17 UTC 2023 , Edited by admin on Fri Dec 15 17:27:17 UTC 2023
|
PRIMARY | |||
|
C174684
Created by
admin on Fri Dec 15 17:27:17 UTC 2023 , Edited by admin on Fri Dec 15 17:27:17 UTC 2023
|
PRIMARY | |||
|
335304
Created by
admin on Fri Dec 15 17:27:17 UTC 2023 , Edited by admin on Fri Dec 15 17:27:17 UTC 2023
|
PRIMARY | |||
|
C018490
Created by
admin on Fri Dec 15 17:27:17 UTC 2023 , Edited by admin on Fri Dec 15 17:27:17 UTC 2023
|
PRIMARY | |||
|
SUB06316MIG
Created by
admin on Fri Dec 15 17:27:17 UTC 2023 , Edited by admin on Fri Dec 15 17:27:17 UTC 2023
|
PRIMARY |
ACTIVE MOIETY